NVCR Overview

NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.

Wall Street analysts forecast NVCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCR is23.58 USD with a low forecast of 13.50 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Novocure Ltd revenue for the last quarter amounts to 174.35M USD, increased 8.11

Novocure Ltd. EPS for the last quarter amounts to -0.22 USD, decreased -63.93

Novocure Ltd (NVCR) has 1605 emplpoyees as of March 26 2026.

Today NVCR has the market capitalization of 1.32B USD.